Biotech Pitch Deck

Even with Biotech companies being among the most funded industries in the VC/PE space, companies still need pitch decks to demonstrate their approach to the market and product demand. Biotech companies require a significant amount of capital and those involved in drug research may not even have a commercialize product. However, investors in this industry are aware of the risks so instead it is better to focus on the potential of the finished, commercialized technology if it passes the FDA pipeline, if needed.

The value proposition section of a biotech pitch deck generally provides information related to what the primary problem in the market is. For many biotech companies, this is the pharmaceutical that it is developing. However, several biotech companies may be associated with hardware or a service in the biotech industry, in which it helps to communicate the significance of the problem faced. In the context of a drug, it helps to point out other drugs that are similar and why they are ineffective and how many people it impacts. Obviously treatments that only impact a small percentage of the population and closely replicate something already on the market is not as appealing as a major treatment discovery for a widespread disease.

Related: Avoid these 7 Pitch Deck Mistakes

The financial projections of a Biotechnology pitch tech generally are broken down in terms of research & development expenses, production costs, and projected demand. If the company produces drugs IMF data of comparable pharmaceuticals are often used as a reference to predict the revenue generation. If the company performs a service or hardware in the industry, the financials are based on the amount of projected users to be generated and the fees associated both with their acquisition and retention.

Related: Approaching Investors for Capital

Only significant employees who are critical to the company's success should be included in your team slide presentation. Avoid highlighting employees who aren't directly related to the job you're doing; a Nobel Laureate in Literature isn't always useful to a biotech firm. Investors want to learn about your team and partners, including any advisers, co-investors, and board members, in a succinct yet engaging way. What makes your team's background and experience stand out? This is the critical tool to highlight prior accomplishments and your network. This might demonstrate to investors that your team is capable of progressing the technology.